2 Stocks That Could Capitalize on the GLP-1 Boom

Two stocks that could benefit from the booming GLP-1 market include CVS Health (NYSE:CVS) and Roche (OTC:RHHBY). CVS Health, a leading pharmacy chain, has seen improved financial results in recent quarters, with revenue increasing 7.3% year-over-year to $106.1 billion and adjusted EPS rising 42.5% to $2.58 in the second quarter.

The company offers a variety of GLP-1 medicines, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy, as well as Low-cost, online assessments and professional support to help patients access these treatments. This expansion of GLP-1 drug coverage could attract more customers and boost sales within CVS Health's pharmacy division.

Roche, a pharmaceutical leader, also has a diverse portfolio of products across different therapeutic areas and operates a diagnostics segment. The company has generated consistent revenue and earnings, with first-half revenue at 30.4 billion Swiss francs ($37.8 billion) and EPS at 10.85 CHF ($13.5) in the first half. Roche is developing promising weight-loss medications, such as CT-388, a dual GLP-1 and GIP agonist, which showed impressive results in a phase 2 study with mean weight loss up to 22.5% after 48 weeks.

If CT-388 progresses through further clinical trials, Roche could become a major player in the GLP-1 category. Despite the risks of clinical setbacks, Roche's deep pipeline and diversified business could help it overcome challenges and continue performing well in the long run.